시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 후천성 자가면역성 용혈성 빈혈 시장 보고서(2025년)
Acquired Autoimmune Hemolytic Anemia Global Market Report 2025
상품코드 : 1760446
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,233,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,010,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,786,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

후천성 자가면역성 용혈성 빈혈 시장 규모는 향후 수 년간 강력한 성장이 전망될 예정입니다. 학술기관의 협력관계 강화, 개별화의료 이용 증가, 고령화 등이 예상됩니다.

자가면역질환의 유병률 증가는 향후 수 년간 후천성 자가면역성 용혈성 빈혈(AIHA) 시장의 성장을 가속할 것으로 예측됩니다. 자가면역 질환은 면역 체계가 신체의 건강한 세포와 조직을 해로운 침입자로 간주하여 잘못 공격할 때 발생합니다. 자가면역 질환의 증가는 주로 면역 체계 조절을 방해하는 환경 요인과 생활 방식의 변화 증가와 관련이 있습니다. 이러한 질환의 유병률이 증가함에 따라 자가면역 질환을 가진 사람들은 면역 체계 조절 장애로 인해 이차성 AIHA에 걸릴 가능성이 높아지기 때문에 후천성 자가면역 용혈성 빈혈의 발생률이 높아집니다. 예를 들어, 2022년 미국의 자가면역 질환 등록 기관 보고서에 따르면, 복합 자가면역 질환으로 진단받은 환자의 비율이 2021년 52%에서 2022년 55%로 증가했습니다.

후천성 자가면역성 용혈성 빈혈 시장의 기업은 치료성적을 개선하고, 부작용을 최소화하고, 환자에 의해 맞춤 치료를 제공하기 위해 인간화 단일클론항체를 포함한 표적요법의 진보에 주목하고 있습니다. 매우 유사하도록 설계된 실험실 수준의 단백질이며, 그 구조의 대부분은 인간이지만, 면역계의 거부 반응을 억제하면서 특정 항원을 표적으로 하는데 도움이 되는 비인간 항체를 약간 포함하고 있습니다. 프랑스에 본사를 두고 있는 건강 관리 기업 Sanofi는 자기 면역성 용혈성 빈혈의 희소형인 한랭 응집소병(CAD)에 대한 최초로 유일한 치료인 Enjaymo(sutimlimab-jome)의 FDA 승인을 취득했습니다. 전적 보체 경로의 C1을 선택적으로 저해하고, 면역계가 건강한 적혈구를 공격하는 것을 막고, CAD 환자에서의 수혈의 필요성을 감소시키고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Acquired autoimmune hemolytic anemia (AIHA) is a rare condition where the immune system mistakenly attacks and destroys the body's red blood cells, leading to anemia. It is often triggered by infections, autoimmune diseases, certain cancers, or specific medications, and can develop either suddenly or gradually. This occurs when the body produces antibodies that target its own red blood cells, resulting in hemolysis, or the early destruction of those cells.

The primary diagnostic methods for acquired autoimmune hemolytic anemia include a complete blood count, peripheral blood smear, direct Coombs test, and indirect Coombs test. A complete blood count (CBC) helps detect anemia by identifying low hemoglobin and hematocrit levels, as well as a higher reticulocyte count, which indicates increased red blood cell destruction. Treatment options vary and can include corticosteroids, immunosuppressive drugs, intravenous immunoglobulin, and rituximab. The severity of the disease ranges from mild to moderate to severe. Key end users of these diagnostic and treatment services include hospitals, specialty clinics, and research institutions.

The acquired autoimmune hemolytic anemia market research report is one of a series of new reports from The Business Research Company that provides acquired autoimmune hemolytic anemia market statistics, including the acquired autoimmune hemolytic anemia industry global market size, regional shares, competitors with the acquired autoimmune hemolytic anemia market share, detailed acquired autoimmune hemolytic anemia market segments, market trends, and opportunities, and any further data you may need to thrive in the acquired autoimmune hemolytic anemia industry. This acquired autoimmune hemolytic anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acquired autoimmune hemolytic anemia market size has grown strongly in recent years. It will grow from $2.01 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period can be attributed to factors such as higher diagnosis rates, an increasing occurrence of secondary AIHA, the expansion of hospital hematology units, support from governments and regulatory bodies, and growing investments in hematology.

The acquired autoimmune hemolytic anemia market size is expected to see strong growth in the next few years. It will grow to $2.88 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period is expected to be driven by the rising incidence of autoimmune diseases, a better understanding of the complement system's role, increased collaboration between biopharma companies and academic institutions, a rise in the use of personalized medicine, and an aging population. Key trends during this period include the adoption of targeted biologic therapies, progress in complement pathway inhibitors, the use of AI and data analytics in disease management, AI-driven clinical trial design, and innovations in orphan drug development.

The growing prevalence of autoimmune disorders is expected to drive the growth of the acquired autoimmune hemolytic anemia (AIHA) market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's own healthy cells and tissues, viewing them as harmful invaders. This rise in autoimmune disorders is mainly linked to increased environmental factors and lifestyle changes that disrupt immune system regulation. The increasing prevalence of these disorders leads to a higher incidence of acquired autoimmune hemolytic anemia, as individuals with autoimmune conditions are more likely to develop secondary AIHA due to immune system dysregulation. For example, in 2022, the autoimmune registry in the United States reported that the percentage of patients diagnosed with multiple autoimmune conditions increased from 52% in 2021 to 55% in 2022. As such, the growing prevalence of autoimmune disorders will contribute to the expansion of the acquired AIHA market.

Companies in the acquired autoimmune hemolytic anemia market are focusing on advances in targeted therapies, including humanized monoclonal antibodies, to improve treatment outcomes, minimize side effects, and offer more personalized care for patients. Humanized monoclonal antibodies are laboratory-engineered proteins designed to closely resemble human antibodies, with a structure that is mostly human but contains small portions of non-human (often mouse) antibodies to help target specific antigens while reducing immune system rejection. For instance, in February 2022, Sanofi, a healthcare company based in France, received FDA approval for Enjaymo (sutimlimab-jome), the first and only treatment for cold agglutinin disease (CAD), a rare form of autoimmune hemolytic anemia. This treatment selectively inhibits C1s in the classical complement pathway, preventing the immune system from attacking healthy red blood cells and reducing the need for transfusions in CAD patients. Enjaymo specifically targets C1-activated hemolysis while leaving the lectin and alternative complement pathways unaffected.

In September 2023, Bristol Myers Squibb, a biopharmaceutical company based in the U.S., acquired the Asian market rights for obexelimab, a bifunctional monoclonal antibody from Zenas BioPharma, for $50 million. This acquisition aims to expand Bristol Myers Squibb's immunology portfolio and strengthen its position in the Asian market for autoimmune disease treatments. Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company that focuses on developing immunology therapies for autoimmune diseases, including acquired autoimmune hemolytic anemia.

Major players in the acquired autoimmune hemolytic anemia market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Rakshit Drugs Private Limited, Aarti Pharmalabs Ltd.

North America was the largest region in the acquired autoimmune hemolytic anemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in acquired autoimmune hemolytic anemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acquired autoimmune hemolytic anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acquired autoimmune hemolytic anemia market consists of revenues earned by entities by providing services such as diagnosis services, treatment and medication services, clinical trials, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired autoimmune hemolytic anemia market also includes sales of prednisone, and methylprednisolone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acquired Autoimmune Hemolytic Anemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acquired autoimmune hemolytic anemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for acquired autoimmune hemolytic anemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acquired autoimmune hemolytic anemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Acquired Autoimmune Hemolytic Anemia Market Characteristics

3. Acquired Autoimmune Hemolytic Anemia Market Trends And Strategies

4. Acquired Autoimmune Hemolytic Anemia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Acquired Autoimmune Hemolytic Anemia Growth Analysis And Strategic Analysis Framework

6. Acquired Autoimmune Hemolytic Anemia Market Segmentation

7. Acquired Autoimmune Hemolytic Anemia Market Regional And Country Analysis

8. Asia-Pacific Acquired Autoimmune Hemolytic Anemia Market

9. China Acquired Autoimmune Hemolytic Anemia Market

10. India Acquired Autoimmune Hemolytic Anemia Market

11. Japan Acquired Autoimmune Hemolytic Anemia Market

12. Australia Acquired Autoimmune Hemolytic Anemia Market

13. Indonesia Acquired Autoimmune Hemolytic Anemia Market

14. South Korea Acquired Autoimmune Hemolytic Anemia Market

15. Western Europe Acquired Autoimmune Hemolytic Anemia Market

16. UK Acquired Autoimmune Hemolytic Anemia Market

17. Germany Acquired Autoimmune Hemolytic Anemia Market

18. France Acquired Autoimmune Hemolytic Anemia Market

19. Italy Acquired Autoimmune Hemolytic Anemia Market

20. Spain Acquired Autoimmune Hemolytic Anemia Market

21. Eastern Europe Acquired Autoimmune Hemolytic Anemia Market

22. Russia Acquired Autoimmune Hemolytic Anemia Market

23. North America Acquired Autoimmune Hemolytic Anemia Market

24. USA Acquired Autoimmune Hemolytic Anemia Market

25. Canada Acquired Autoimmune Hemolytic Anemia Market

26. South America Acquired Autoimmune Hemolytic Anemia Market

27. Brazil Acquired Autoimmune Hemolytic Anemia Market

28. Middle East Acquired Autoimmune Hemolytic Anemia Market

29. Africa Acquired Autoimmune Hemolytic Anemia Market

30. Acquired Autoimmune Hemolytic Anemia Market Competitive Landscape And Company Profiles

31. Acquired Autoimmune Hemolytic Anemia Market Other Major And Innovative Companies

32. Global Acquired Autoimmune Hemolytic Anemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acquired Autoimmune Hemolytic Anemia Market

34. Recent Developments In The Acquired Autoimmune Hemolytic Anemia Market

35. Acquired Autoimmune Hemolytic Anemia Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기